Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (NCT04268550)

🧪 Interventions in This Study

• Selpercatinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (306 Sites)

Showing the first 25 of 306 sites.

• Fairbanks Memorial Hospital — Fairbanks, Alaska
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• Kaiser Permanente-Anaheim — Anaheim, California
• Sutter Auburn Faith Hospital — Auburn, California
• Kaiser Permanente-Baldwin Park — Baldwin Park, California
• Kaiser Permanente-Bellflower — Bellflower, California
• Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
• Kaiser Permanente-Fontana — Fontana, California
• Palo Alto Medical Foundation-Fremont — Fremont, California
• Kaiser Permanente - Harbor City — Harbor City, California
• Kaiser Permanente-Irvine — Irvine, California
• Loma Linda University Medical Center — Loma Linda, California
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
• Kaiser Permanente-Cadillac — Los Angeles, California
• Palo Alto Medical Foundation-Camino Division — Mountain View, California
• Kaiser Permanente-Ontario — Ontario, California
• Palo Alto Medical Foundation Health Care — Palo Alto, California
• Stanford Cancer Institute Palo Alto — Palo Alto, California
• Kaiser Permanente - Panorama City — Panorama City, California
• Kaiser Permanente-Riverside — Riverside, California
• Sutter Roseville Medical Center — Roseville, California
• Sutter Medical Center Sacramento — Sacramento, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• Kaiser Permanente-San Diego Zion — San Diego, California
• California Pacific Medical Center-Pacific Campus — San Francisco, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Recurrent Lung Non-Small Cell Carcinoma

• Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer — Houston, Texas
• Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer — Scottsdale, Arizona
• NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer — Houston, Texas
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study — Birmingham, Alabama
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer — Anchorage, Alaska

Explore by condition: All Recurrent Lung Non-Small Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.